SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lannett Company, Inc. of Class Action Lawsuit and Upcoming Deadline - LCI
31 Aug, 2018, 22:57 BST
NEW YORK, Aug. 31, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI) and certain of its officers. The class action, filed in United States District Court, Eastern District of Pennsylvania, and docketed under 18-cv-3635, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Lannett securities between February 7, 2018 through August 17, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
If you are a shareholder who purchased Lannett securities between February 7, 2018, and August 17, 2018, both dates inclusive, you have until October 26, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
[Click here to join this class action]
Lannett develops, manufactures, packages, markets, and distributes solid oral (tablets and capsules), extended release, topical, and oral solution finished dosage forms of drugs that address a wide range of therapeutic areas. Lannett also produces, through its subsidiary Cody Laboratories, Inc., active pharmaceutical ingredients. Lannett derives the majority of its revenue from the sale of drugs that are bioequivalent to certain patented drugs once their patent expires.
At all relevant times, Lannett has had an exclusivity agreement with its primary supplier, Jerome Stevens Pharmaceuticals ("JSP"), owned and operated by the Steinlauf family, set to expire on March 23, 2019. JSP's products have historically accounted for at least one-third of Lannett's sales.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose that: (i) Lannett faced a substantial risk of the loss of its exclusivity agreement with JSP; (ii) accordingly, Lannett's reported revenues were unsustainable, and (iii) as a result, Lannett's public statements were materially false and misleading at all relevant times.
On August 20, 2018, prior to market open, Lannett announced that its distribution agreement with JSP will not be renewed upon its expiration in March 2019. Lannett stated that it "intend[ed] to redouble our continuing efforts to explore options for addressing our capital structure."
On this news, Lannett's share price fell $8.15, or 60.3%, to close at $5.35 on August 20, 2018.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 9980
Related Links
SOURCE Pomerantz LLP